Search
Tilsotolimod
go.drugbank.com/drugs/DB16341InvestigationalTilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)).
WP-1122
go.drugbank.com/drugs/DB17192InvestigationalIt was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]
Synonyms: 3,6-di-O-acetyl-2-deoxy-D-glucopyranoseSquaric acid dibutyl ester
go.drugbank.com/drugs/DB12223InvestigationalSquaric acid dibutyl ester is under investigation in clinical trial NCT01971385 (Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis).
GLB-005
go.drugbank.com/drugs/DB32797ExperimentalGLB-005 is a molecular glue degrader targeting WIZ and is being investigated for treatment of sickle cell disease and β-thalassemia.[L56125, L56126, L56128]
Dihydroxyacetone phosphate
go.drugbank.com/drugs/DB04326InvestigationalDihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.
Ginsenoside Rg1
go.drugbank.com/drugs/DB06750ExperimentalNutraceuticalBecause ginsenosides appear to affect multiple pathways, their effects are complex and difficult to isolate. Rg1 Appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng).
ECT-001 expanded cord blood
go.drugbank.com/drugs/DB21745Investigational[L52013] It is being investigated in hematopoietic cell transplantation as ECT-001 expanded cord blood can demonstrate enhanced stem cell proliferation and engraftment compared to untreated UBCs. … ECT-001 expanded cord blood is umbilical cord blood (UCB) that has been co-cultured and expanded with the small molecule agonist [UM-171].
(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene
go.drugbank.com/drugs/DB08264ExperimentalThis compound belongs to the naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
NTLA-2002
go.drugbank.com/drugs/DB17597InvestigationalIt is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]